IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

"Drug Repurposing: A Novel Approach in CADD"

[a]Prof. Mohammed Faisal (M. Pharm. Pharmaceutical chemistry) [b]Miss. Nivedita N. Patil, Mr. Pratik B. Jadhav, Mr. Nilesh S. Ahire, Miss. Jagruti B. Hyalij

[a]Professor of Swami Vivekanand Sanstha's Institute of Pharmacy Malegaon, Nashik 423201 [b]Student's of Swami Vivekanand Sanstha's Institute of Pharmacy Malegaon, Nashik 423201

Abstract

The process of discovering and developing new medications is often regarded as a lengthy, complex, and expensive endeavor, necessitating innovative strategies to enhance efficiency and reduce costs. ComputerAided Drug Design (CADD) has emerged as a transformative approach, utilizing computational tools to streamline drug discovery and development. Among the various CADD methodologies, structure-based and ligand-based drug design are particularly prominent due to their efficacy in identifying and optimizing potential leads, often in conjunction with molecular docking and virtual screening techniques. In parallel, drug repurposing has gained attention as a novel approach to drug discovery, focused on identifying new therapeutic indications for existing drugs. This strategy significantly reduces development timelines and costs while increasing the likelihood of regulatory approval. Drug repurposing leverages both serendipitous discoveries and hypothesis-driven methodologies, including experimental and computational techniques such as the Connectivity Map (CMap) approach. These computational tools enhance understanding of drugdisease-gene interactions and serve as catalysts for repurposing efforts. From Sildenafil's repurposing for erectile dysfunction to Tocilizumab's role in COVID-19 treatment, numerous success stories underscore the potential of drug repurposing. However, distinct regulatory pathways and challenges, such as limited marketing exclusivity, highlight the complexities of this approach. This review explores the key computational methods in CADD and drug repurposing, provides insights into regulatory frameworks, examines notable case studies, and discusses the challenges and opportunities in this rapidly evolving field. Together, these strategies offer promising avenues for addressing unmet medical needs, including rare genetic disorders and cancers.

Keypoints

Drug Repurposing, Computer-Aided Drug Design (CADD), Structure-Based Drug Design (SBDD), Ligand-Based Drug Design (LBDD), Molecular Docking and Virtual Screening, Regulatory Pathways and Challenges.

Introduction

The development of new therapeutic agents is a critical endeavor in modern medicine, yet it is often accompanied by significant challenges. The traditional process of discovering and developing a new drug is notoriously time-consuming, typically spanning over a decade, and financially burdensome, with costs reaching billions of dollars. In this context, innovative strategies have emerged to enhance efficiency and reduce the time and resources required for drug discovery. One such innovation is **Computer-Aided Drug Design (CADD)**, which leverages computational tools to predict drug-target interactions, streamline lead identification, and optimize drug candidates. Among the prominent methodologies in CADD, **StructureBased Drug Design (SBDD)** and **Ligand-Based Drug Design (LBDD)** have proven to be powerful approaches for identifying and

refining potential therapeutic agents. Coupled with techniques such as molecular docking and virtual screening, these approaches significantly accelerate the early stages of drug discovery.

Complementing these computational strategies is the concept of **drug repurposing**, which involves finding new therapeutic indications for existing drugs. This approach offers a promising alternative to traditional drug discovery by utilizing the safety and pharmacokinetic profiles of known compounds. Drug repurposing has been instrumental in addressing urgent medical needs, as evidenced by the repurposing of Sildenafil for erectile dysfunction and Tocilizumab for COVID-19. It is a strategy that not only reduces development costs and timelines but also increases the probability of regulatory approval.

This review delves into the intersection of CADD and drug repurposing, highlighting their methodologies, successes, and challenges. By examining the regulatory pathways, computational tools, and notable examples, we aim to provide a comprehensive understanding of how these approaches are revolutionizing drug discovery and addressing unmet medical needs, including those in rare diseases and oncology.



Fig. 1 Development Pipeline

Structure-Based Drug Design (SBDD)

Structure-Based Drug Design (SBDD) is a computational approach to drug discovery that utilizes the threedimensional (3D) structure of a target protein. This method is particularly valuable in identifying and optimizing therapeutic molecules by analyzing their interactions with the target's active site. The availability of structural data for proteins has revolutionized the drug discovery process, providing precise insights into molecular interactions and enabling the rational design of highly specific drugs.

1. **Target Protein Structure:**
    - SBDD relies on the known 3D structure of the target protein, which is typically obtained through experimental methods such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy.
    - Databases like the Protein Data Bank (PDB) provide structural information for over 100,000 proteins, enabling researchers to access detailed molecular models for drug design.

2.Molecular Docking:

- In SBDD, candidate compounds are docked into the binding site of the target protein using computational algorithms.

- The docking process predicts how the compound interacts with the target and calculates metrics such as binding affinity, orientation, and stability of the complex.

3. **Interaction and Bio-Affinity Analysis:**
   - The interactions between the docked compound and the target protein, including hydrogen bonds, hydrophobic interactions, and electrostatic forces, are analyzed to assess the binding efficiency.
   - The bio-affinity score helps rank compounds based on their potential effectiveness.
4. **Therapeutic Molecule Design:**
   - Based on docking results, new therapeutic molecules are designed or optimized to improve their binding affinity, specificity, and drug-like properties.
   - Iterative design and testing allow researchers to refine the molecular structure for better therapeutic potential.



Fig. 2 Structure-based drug design (SBDD) process

Ligand-Based Drug Design (LBDD)

Ligand-Based Drug Design (LBDD) is a computational strategy used in drug discovery when the threedimensional (3D) structure of the target protein is unknown or unavailable. In LBDD, the focus shifts to the known ligands that interact with the target, such as previously discovered small molecules or compounds with similar biological activity. By analyzing the structural and chemical properties of these ligands, LBDD aims to design new molecules or optimize existing ones that can bind to the target's active site with high affinity and specificity.

The key assumption in LBDD is that molecules with similar structures tend to exhibit similar biological activities. This allows for the identification of new compounds that could act as potential therapeutics by studying the properties of known binders to the target.



Fig. 3 Ligand-Based Drug Design (LBDD)

1. **Ligands and Active Site Identification:**

   - In LBDD, the 3D structure of the target protein is not required, but information about ligands that bind to the target is essential. Ligands are molecules that bind to a specific protein target and can either activate or inhibit its function.
   - These ligands are typically identified from previous experimental data or through virtual screening. The next step is to extract the relevant structural and chemical features of these ligands that facilitate binding to the target's active site.

Pharmacophore Model:

   - A **pharmacophore** is a theoretical model that represents the essential chemical features required for a molecule to interact with a specific biological target. It identifies the key functional groups (such as hydrogen bond donors/acceptors, hydrophobic regions, and aromatic rings) that must be present in a molecule for effective binding to the target.
   - In LBDD, pharmacophore modeling is used to design or identify new molecules by matching these features with potential drug candidates. The pharmacophore-based method relies on the assumption that compounds sharing similar pharmacophore features will exhibit similar binding interactions and biological activity.

3. **Quantitative Structure-Activity Relationship (QSAR):**

   - **QSAR modeling** is a mathematical approach used to predict the biological activity of compounds based on their molecular structure. The core idea behind QSAR is that there is a relationship between the chemical structure of a compound and its biological activity. By creating a QSAR model, researchers can predict the activity of new compounds that have not yet been tested experimentally.

- QSAR typically involves the calculation of molecular descriptors (such as molecular size, shape, hydrophobicity, and electronic properties) and correlating these with experimental data on biological activity. The resulting model can then be used to identify or design new drug candidates with improved potency, selectivity, or reduced toxicity.

4. **Ligand Similarity and Virtual Screening:**

   - One of the fundamental assumptions of LBDD is that compounds with similar structures will likely bind to the same or similar binding sites and exhibit similar biological effects. This allows for the use of **ligand-based virtual screening** to identify new drug candidates by comparing them to known ligands that bind to the target.

   - Virtual screening tools search large compound libraries to identify molecules with structural similarities to the known ligands. These molecules are then ranked based on their predicted ability to bind to the target, which helps in selecting compounds for further experimental testing.

Virtual Screening

Virtual screening (VS) is a computational technique used to evaluate large libraries of chemical compounds and predict which ones are most likely to bind to a specific biological target, such as a protein or enzyme. This method enables researchers to filter through vast numbers of compounds without needing to perform extensive laboratory experiments, making it a cost-effective and time-efficient alternative to traditional high-throughput screening (HTS). Virtual screening has become an essential tool in drug discovery, particularly in the early stages, where the goal is to identify potential hit compounds for further experimental validation.

Virtual screening works by applying computational algorithms to model interactions between compounds and biological targets, thus predicting which compounds are most likely to be bioactive. These predictions are based on structural or chemical information about the target and the compound library, allowing for more informed decision-making in drug design.



Fig. 4 Virtual screening

Types of Virtual Screening Approaches

There are two primary approaches to virtual screening: **structure-based virtual screening (SBVS)** and **ligand-based virtual screening (LBVS)**. Both have their strengths and applications, depending on the availability of structural information and the specific goals of the drug discovery process. **1. Structure-Based Virtual Screening (SBVS) Definition:**

Structure-based virtual screening (SBVS) involves using the three-dimensional (3D) structure of the target protein (or its active site) to predict which compounds are most likely to bind to it. SBVS relies on the availability of detailed structural data, which is typically obtained through techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy (cryo-EM). If the target structure is not available, SBVS can still be performed by homology modeling, where a 3D model of the protein is generated based on a known homologous structure.

Process:

1. **Target Protein Structure:** The first step in SBVS is to obtain or generate the 3D structure of the target protein. This could be obtained from the Protein Data Bank (PDB) or determined experimentally. If no structure is available, computational methods like homology modeling are used to generate a model.

   Active Site Identification: The active site or binding pocket of the target protein is identified. This is the region where small molecules or ligands will interact with the protein. Identifying the key features of the binding site is essential to successful virtual screening.

3. **Compound Library Selection:** A chemical compound library is then selected for screening. This library can consist of natural compounds, synthetic chemicals, or a combination of both.

4. **Molecular Docking:** The compounds in the library are "docked" into the active site of the target protein using molecular docking software. During docking, the software simulates how each compound fits into the binding site, considering factors like shape complementarity, electrostatic interactions, and hydrogen bonding.

5. **Scoring and Ranking:** Each compound is assigned a docking score based on how well it fits into the binding site. These scores can predict the binding affinity of the compound to the target protein. Compounds with the highest scores are considered the most promising candidates for experimental testing.

Applications of SBVS:

- **Targeted Drug Discovery:** SBVS is commonly used to identify small molecules that specifically target a disease-related protein or enzyme, such as inhibitors for cancerous proteins or viral targets.
- **Hit Identification:** SBVS is highly effective for identifying potential "hit" compounds that can be further optimized into drug candidates.
- **Fragment-Based Drug Design:** SBVS is also useful in fragment-based drug discovery, where small molecular fragments are docked into the target binding site to create a larger, more potent drug.

2. Ligand-Based Virtual Screening (LBVS) Definition:

Ligand-based virtual screening (LBVS) is a method used when the 3D structure of the target protein is unknown or difficult to obtain. In LBVS, the focus is placed on the known ligands that have been shown to interact with the target. This approach relies on calculating the structural similarity between the known active ligands and a large compound database to predict which compounds are most likely to bind to the target.

Process:

1. **Known Ligands Selection:** In LBVS, the first step is identifying known ligands that have been previously shown to interact with the target. These ligands could be from experimental data, literature, or existing drugs that act on similar targets.

2. **Ligand-Activity Relationship Analysis:** The known ligands are analyzed to identify common structural features that contribute to their binding affinity to the target. These features can include functional groups (such as hydrophobic regions, hydrogen bond donors/acceptors, and aromatic rings).

3. **Pharmacophore Modeling:** A **pharmacophore model** is created, which is a 3D representation of the essential features required for a ligand to bind to the target's active site. The pharmacophore acts as a template to search for compounds that share these features.

4. **Similarity-Based Screening:** A compound library is then screened for new molecules that match the pharmacophore model. The screening process calculates the similarity between the known ligands and compounds in the library, based on structural features like shape, functional groups, and charge distribution.

5. **Scoring and Ranking:** Similarity scoring is applied to rank compounds based on how well they align with the pharmacophore. Compounds with the highest similarity scores are considered to have the highest potential for binding to the target.

Applications of LBVS:

- **Target Identification and Drug Repurposing:** LBVS can be used to identify compounds that may act on a new target, especially when detailed structural information is lacking. It is also frequently employed in drug repurposing efforts, where known active compounds are screened for potential new targets.
- **Lead Optimization:** After identifying initial hits, LBVS can be used to optimize leads by searching for similar compounds with better binding profiles or improved drug-like properties.
- **Fragment-Based Screening:** LBVS can be applied in fragment-based drug discovery to identify smaller chemical fragments that could bind to the target.

Molecular Docking

Molecular docking is a computational method used to predict the binding interactions between small molecules (ligands) and their target proteins (receptors). This technique is crucial for drug discovery, as it allows researchers to simulate how a drug molecule fits into the binding site of a target protein, predict its binding affinity, and assess its potential for biological activity. Molecular docking has become an essential tool in structure-based drug design (SBDD), particularly for virtual screening and lead optimization, as it aids in the identification of promising compounds from large compound libraries.

Molecular docking involves simulating the interaction between the ligand and the receptor to estimate the most favorable binding mode, as well as the strength of their interaction. The main objectives of molecular docking include the prediction of binding posture, calculation of binding affinity, and conducting virtual screening of compound libraries to identify potential drug candidates.

Key Concepts in Molecular Docking

1. Binding Posture Prediction:

One of the primary goals of molecular docking is to predict the binding mode or posture of a ligand when it binds to its target protein. The binding posture refers to the exact orientation and position of the ligand within the receptor's binding site. The binding site is the specific region of the protein where the ligand interacts, often characterized by specific amino acid residues that form interactions like hydrogen bonds, hydrophobic interactions, or electrostatic forces with the ligand.

Docking simulations predict the most stable and energetically favorable conformation of the ligand within the receptor's binding site. This prediction is crucial for understanding how the ligand fits into the target and whether it could effectively interact with the protein to modify its function.

2. Binding Affinity Estimation:

Binding affinity is a measure of how strongly a ligand binds to its receptor. Molecular docking algorithms predict the binding affinity by calculating the strength of the interaction between the ligand and the receptor. The higher the binding affinity, the stronger the interaction, and the more likely the ligand is to have a biological effect on the receptor.

Binding affinity is typically estimated using scoring functions that evaluate the interactions between the ligand and receptor, considering factors such as hydrogen bonding, van der Waals forces, and electrostatic interactions. The resulting score can be used to rank compounds in a virtual screening process to identify those with the highest potential for further experimental validation.

3. Virtual Screening:

Molecular docking is widely used in virtual screening, where a large library of compounds is computationally tested to predict which ones are most likely to bind to a specific protein target. Virtual screening allows researchers to filter large numbers of compounds and identify potential hits for further experimental testing, thus reducing the time and cost associated with high-throughput screening.

Molecular docking in virtual screening involves docking each compound from the library into the receptor's binding site, predicting their binding modes, and calculating their binding affinities. The compounds are then ranked based on their docking scores, and the highest-scoring compounds are selected for further validation and optimization.

Components of Molecular Docking:

Molecular docking involves two main components: the **search algorithm** and the **scoring algorithm**. Both are essential for generating and evaluating ligand conformations.

1. Search Algorithm:

The search algorithm is responsible for exploring the possible binding modes of the ligand within the receptor's binding site. It generates different conformations of the ligand by altering its position, orientation, and conformation to fit within the target's binding pocket. The algorithm aims to find the most energetically favorable binding pose of the ligand.

There are different types of search algorithms used in molecular docking:

- **Rigid Docking:** In this approach, both the receptor and ligand are considered rigid, with no flexibility allowed during docking. This method is simpler and faster but less accurate, as it does not account for the flexibility of the protein or ligand.
- **Flexible Docking:** This method allows both the receptor and ligand to undergo conformational changes during docking. It is more accurate and realistic since it accounts for the flexibility of both the ligand and protein, but it is computationally more demanding.
- **Docking with Ligand Flexibility:** The ligand is allowed to adopt different conformations or rotamers, while the protein remains fixed. This is more efficient than fully flexible docking but still accounts for important variations in ligand flexibility.

2. Scoring Algorithm:

The scoring algorithm is used to evaluate the binding affinity between the ligand and the receptor based on the predicted binding mode. The goal of the scoring function is to assign a numerical value to each ligandreceptor complex that reflects the stability and strength of their interaction.

Scoring functions are designed to predict the free energy of binding, which is the difference between the energy of the ligand-receptor complex and the energies of the separate components (ligand and receptor).
A lower energy or higher score typically indicates a stronger binding interaction.

There are several types of scoring functions:

- **Force Field-Based Scoring:** These functions calculate the energy of the ligand-receptor complex using a set of physical principles and force fields, such as van der Waals forces, electrostatic interactions, and hydrogen bonding.
- **Empirical Scoring:** These scoring functions use a database of known protein-ligand complexes to generate a model for predicting binding affinity. The scoring function is calibrated using experimental data from known protein-ligand interactions.
- **Knowledge-Based Scoring:** These scoring functions rely on statistical analysis of protein-ligand complexes in the protein data bank (PDB) to determine the likelihood of specific interactions.

The chosen scoring algorithm plays a significant role in determining the accuracy of docking predictions. Different docking programs use different scoring functions, and the selection of the scoring function can impact the reliability of the results.

Conclusion:

Drug repurposing, as a novel approach in Computer-Aided Drug Design (CADD), holds significant promise in accelerating the drug discovery process while minimizing time and costs. By leveraging computational techniques, such as structure-based and ligand-based drug design, along with molecular docking and virtual screening, researchers can identify potential new uses for existing drugs, including those that have failed in previous clinical trials or were withdrawn from the market. These computational approaches streamline the process of drug repurposing, enhancing the probability of success and offering a more efficient pathway to bring therapies to market. The ability to repurpose drugs for new indications not only presents an opportunity to find treatments for rare diseases and conditions that may not attract extensive research funding but also enables faster entry into clinical settings compared to novel drug discovery. The use of bioinformatics tools and computational methods, like the Connectivity Map (CMap) and quantitative structure-activity relationship (QSAR) models, further aids in pinpointing relevant gene-disease-drug connections, making drug repurposing a powerful tool for addressing unmet medical needs.

While drug repurposing offers substantial benefits, challenges related to regulatory pathways, intellectual property concerns, and the need for further clinical validation remain. Nonetheless, the integration of CADD into the drug repurposing process is a significant step forward, and as computational technologies continue to evolve, they will likely play an even more pivotal role in transforming drug discovery and development. Thus, drug repurposing, combined with the advancements in CADD methodologies, represents a promising strategy to address complex diseases and improve public health outcomes efficiently and cost-effectively.

References

1) Maithri G, Manasa B, Vani SS, Narendra A, Harshita T. Computational drug design and molecular dynamic studies—a review. Biomedical Data Mining. 2016; 5:1-7.
2) Lill M. Virtual screening in drug design. In Silico Models for Drug Discovery. 2013 Vol. 993, pp. 1-12. Humana Press,Totowa, NJ.
3) Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Archives of pharmacal research. 2015; 38(9):1686-701.
4) Hoque I, Chatterjee A, Bhattacharya S, Biswas R. An Approach of Computer-Aided Drug Design (CADD) Tools for In Silico Pharmaceutical Drug Design and Development. Int. J. Adv. Res. Biol. Sci. 2017; 4(2) 60-71.

5) Anderson AC. The process of structure-based drug design.Chemistry & biology. 2003; 10(9):787-97.
6) Ferreira LG, dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7):13384-421.
7) Imam SS, Gilani SJ. Computer Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem. 2017; 1(4):1 6.
8) Hopfinger AJ. Computer-assisted drug design. Journal of medicinal chemistry. 1985; 28(9):1133-9
9) Xiang M, Cao Y, Fan W, Chen L, Mo Y. Computer-aided drug design: lead discovery and optimization. Combinatorial chemistry & high throughput screening. 2012; 15(4):328-37.
10) Daina A, Blatter MC, Baillie Gerritsen V, Palagi PM, Marek D, Xenarios I, et al. Drug Design Workshop: A Web Based Educational Tool To Introduce Computer-Aided Drug Design to the General Public. Journal of Chemical Education. 2017; 94(3):335-44.
11) Gleeson, M.P., and D. Montanari. Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization. Expert Opin. Drug Metab. Toxicol. 2012; 8: 1435–1446. 8
12) Cruciani, G., E. Carosati, B. De Boeck, K. Ethirajulu, C. Mackie, T. Howe, and R. Vianello. MetaSite: Understanding metabolism in human cytochromes from the perspective of the chemist. J. of Med. Chem. 2005; 48: 6970–6979.
13) Rydberg, P., D.E. Gloriam, J. Zaretzki, C. Breneman, and L. Olsen. SMARTCyp: A 2D method for prediction of cytochrome P450-mediated drug metabolism. ACS Med. Chem. Lett. 2010; 1: 96–100.
14) Ananthula, R.S., M. Ravikumar, A.B. Pramod, K.K. Madala, and S.K. Mahmood. Strategies for generating less toxic P-selectin inhibitors: Pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits. J. of Mol. Graph. Model. 2008; 27: 546–557.
15) Jeffrey, P., and S. Summerfield. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol. of Diseases. 2010; 37: 33–37.
16) Lagorce, D., O. Sperandio, H. Galons, M.A. Miteva, and B.O. Villoutreix. FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects. BMC Bioinformatics. 2008; 9: 396.
17) Lagorce, D., J. Maupetit, J. Baell, O. Sperandio, P. Tuffery, M.A. Miteva, H. Galons, and B.O. Villoutreix. The FAF Drugs2 server: A multistep engine to prepare electronic chemical compound collections. Bioinformatics. 2011; 27: 2018–2020.
18) Athanasiadis, E., Z. Cournia, and G. Spyrou. ChemBioServer: A web-based pipeline for filtering, clustering and visualization of chemical compounds used in drug discovery. Bioinformatics. 2012; 28: 3002–3003.
19) Veber, D.F., S.R. Johnson, H.Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple. Molecula